What question did this study set out to answer?

To quantify allelic and genotypic frequencies of CYP2C19 loss-of-function (*2, *3) and gain-of-function (*17) variants and predict drug-metabolizing phenotypes in a healthy population.

May 20, 2023Indian Heart JournalOpen Access

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals

View Full Paper

Ask AI

Bookmark

Why the study?

It is essential to investigate the prevalence of CYP2C19 alleles affecting drug metabolism, specifically CYP2C19 loss-of-function and gain-of-function alleles in the general population.

Population

300 healthy subjects between the ages of 18 and 85

Design

Cross-sectional genetic study

Authors

AYAnshu YadavJSS Academy of Higher Education and Research ACAparna Kodakkat ChakkumkollathJSS Academy of Higher Education and Research AHAysha HelnaJSS Academy of Higher Education and Research

Discussion

Member takes

Implication

High intermediate/poor CYP2C19 prevalence may support genotyping consideration before clopidogrel in Indians; leaves open outcome trials.

Key Points

To quantify allelic and genotypic frequencies of CYP2C19 loss-of-function (*2, *3) and gain-of-function (*17) variants and predict drug-metabolizing phenotypes in a healthy population.
Recruited 300 healthy individuals aged 18 to 85 years using simple random sampling.
Identified CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles via allele-specific touchdown PCR and evaluated Hardy-Weinberg equilibrium.
Classified subjects into ultra-rapid (UM), extensive (EM), intermediate (IM), and poor metabolizer (PM) phenotypes based on genotype.
Allele frequencies were 0.365 for CYP2C19*2, 0.0033 for CYP2C19*3, and 0.18 for CYP2C19*17.
Phenotypic distribution showed intermediate metabolizers predominated at 46.67% (n=140), followed by extensive metabolizers at 35.00% (n=105), poor metabolizers at 12.67% (n=38), and ultra-rapid metabolizers at 5.67% (n=17).

Structured PICO

Population

300 healthy subjects between the ages of 18 and 85 recruited by simple random sampling

Outcome

Allelic and genotypic frequencies of CYP2C19 loss-of-function (LoF) alleles CYP2C19*2, CYP2C19*3, and gain-of-function (GoF) alleles CYP2C19*17surrogate

The high prevalence of intermediate and poor CYP2C19 metabolizer phenotypes (combined ~59%) in this healthy cohort highlights the potential importance of genetic testing prior to clopidogrel administration.

Cite This Study

Yadav et al. (2023) studied this question.

synapsesocial.com/papers/6a8bebe4e6afc07dcbf45ee7 https://doi.org/10.1016/j.ihj.2023.05.005

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider